search

Active clinical trials for "Precursor Cell Lymphoblastic Leukemia-Lymphoma"

Results 291-300 of 1817

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Philadelphia-Positive ALLAcute Lymphoblastic Leukemia1 more

This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in the few patients who never achieved an hematologic remission after whatever prior treatment.

Recruiting29 enrollment criteria

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients...

B-ALLDLBCL11 more

This is a single-cohort pilot study; patients will receive 131-I apamistamab 75 mCi prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab.

Recruiting36 enrollment criteria

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...

Acute Biphenotypic LeukemiaAcute Leukemia10 more

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.

Recruiting51 enrollment criteria

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute LeukemiaAcute Myeloid Leukemia27 more

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Recruiting56 enrollment criteria

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic...

Chronic Lymphocytic LeukemiaMantle Cell Lymphoma3 more

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies.

Recruiting29 enrollment criteria

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive...

Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

The Primary objective is to assess the non-inferiority of the experimental arm (arm B) compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the 4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL)

Recruiting40 enrollment criteria

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological...

Acute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)16 more

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).

Recruiting24 enrollment criteria

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents,...

B-cell Acute Lymphoblastic Leukemia

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).

Recruiting32 enrollment criteria

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Recruiting10 enrollment criteria

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Acute Lymphoblastic Leukemiain Relapse2 more

Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of patients, since their synergy with drugs such as steroids has positioned them as an attractive strategy.

Recruiting8 enrollment criteria
1...293031...182

Need Help? Contact our team!


We'll reach out to this number within 24 hrs